PRA7
REGISTERED - SEC. 7 REQUEST ABANDONED
29/06/2026
Voltar para busca
Dado oficial do USPTO
CSL SEQIRUS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
CSL SEQIRUS
ST13
US500000097542504Classe
1, 5, 41, 42, 44
Pedido
97542504
Registro
7877427
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
45
Atualização mais recente
29/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 41, 42, 44
Data de depósito
10/08/2022
Data de registro
05/08/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/08/2025
Última transação
29/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
Maidenhead, Berkshire, GB
Examinador
CAYSIDO, REBECCA TOLENTINO
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Seqirus UK Limited
Representantes
Nancy Sabarra FROSS ZELNICK LEHRMAN & ZISSU, P.C.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 41Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical and biological reagents for scientific purposesresearch purposesnon-medical purposes; cell culture reagents and media for scientific and research use; laboratory and scientific test kits for laboratory or research usereagent kits comprising generic DNA circleDNA primerspolymerase and buffers for use in biotechnology fields; chemical preparations for scientific and industrial purposes; diagnostic and testing agentsdiagnostic reagents and diagnostic testing preparations for scientific and research use; chemical and biological reagents for non-medical purposes; chemical and biological reagents for industrial use for antibody screeningblood groupingfor the typing and detection of specific blood cellsdetermining the presence of antigens on blood cellsthe detection of relevant complement compounds and immunoglobulin subtypes all for non-medical purposes; chemical test kits for the detection of specific blood cellsdetermining the presence of antigens on blood cellsthe detection of relevant complement compounds and immunoglobulin subtypes for laboratory or research use; chemical preparations for industrial use for anti-body screeningblood groupingthe typing and detection of specific blood cells
Classe 5
Pharmaceutical preparations and substances for the treatment and prevention of influenzarespiratory disease and disordersinfectious diseases and disorderscardiovascular diseases and disordersstrokeheart failure; pharmaceutical preparations and substancesanti-virals and antibiotics; vaccines; blood productsblood for medical purposesblood plasma and cord blood for medical purposes; serumsanti-venoms; medicated serums for the treatment of blood disorders and bleeding disorders; antibodies for use in the treatment of infectious diseasescancer and autoimmune diseases; monoclonal and polyclonal antibodies for medical purposes; therapeutic monoclonal and polyclonal antibodies and antibodies for use in the treatment of infectious diseases; influenza vaccines; adjuvants for medical purposes and antigens being protein arrays for medical purposes; pharmaceutical preparations and substances for the treatment and prevention of blood or bleeding disorders; blood productsblood plasmareagent blood cells for medical use; products derived from blood and products derived from recombinant DNA technologyblood substitutes being immunoglobulinshuman albuminblood clotting factorsplasma volume expandersblood proteins for therapeutic human use; test kitsinvitro diagnostic reagent test kits comprised of medical diagnostic reagents for use in detecting cell mediated immune response; pharmaceutical preparations and substancesRhD reagents for medical use for the detection of specific antigens and in blood typing; pharmaceutical preparationsreagent red blood cells for medical purposes used to detect antibodies or IgG subtypes; pharmaceutical preparationsmonoclonal and polyclonal antibodies for pharmaceutical use; pharmaceutical preparationsreagents for medical and clinical use for the typing and detection of specific blood cellsthe detection of relevant compliment components and immunoglobulin subtypes; diagnostic agents for medical purposes
Classe 41
Education services including medical education servicesconducting classesseminarsconferencesworkshops in the fields of pharmaceuticalsvaccinesbiotechnologybiotherapyimmunologyrare diseases and blood conditions; health educationproviding classes in the field of healthvaccinesimmunology; consultancy services relating to education; provision of education servicesarranging and conducting of online conferences and symposia in the field of medical science via an online forum; provision of medical training and education courses in the field of health and medicine; publication of electronic educational materials; dissemination of printed and electronic educational material of others in the field of health and medicine; weblog servicesproviding online non-downloadable blogs in the field of health and medicine; electronic publication of information on a wide range of topicsincluding online and over a global computer networkelectronic publishing of electronic publications featuring information on a wide range of topics
Classe 42
Scientific and technological servicesscientific research and product development in the field of vaccines; scientific researchanalysistesting in the field of medicinepharmaceuticalsvaccinesbiotechnology; research and development servicesscientificmedicalpharmaceutical and blood products research and development services; industrial analysis of biotechnology and immunology processes for product development in the field of pharmaceuticals and vaccines; providing medical research and scientific research information about the results of clinical trials for pharmaceuticals and vaccines; providing medical research and scientific research information in the field of clinical trials; provision of testing facilities for pharmaceutical research; laboratory analysis and research in the fields of pharmaceuticalsvaccinesbacteriologychemistry; management of scientific research projects; providing technical research in the field of pharmaceutical studies through preparation of technical studiestechnical reportsscientific reports; providing technical research in the field of pharmaceutical studies through preparation of scientific and medical research projectspreparation of statistics and reports relating to scientific and medical research; provision of scientific research services and facilitiesprovision of scientific research resultsinformation and outcomes in the field of health and medicine; provision of pharmaceutical research information relating to the aforementioned services; pharmaceutical research advisory and consultancy services relating to the aforementioned services; dissemination of pharmaceutical research and medical research information relating to the aforementioned services over a global computer network; medical laboratory services through scientific testing and screening servicesmedical laboratory testing of human blood plasma for safety and quality; medical laboratory services regarding human blood plasma
Classe 44
Medical services; medical information services; health care services; health care information services; patient support servicesproviding an internet-based database of patient medical information where patients can inquire about medical issues and procedures related to vaccination and immunology; providing medical information concerning blood products; providing medical information concerning vaccinesanti-venoms and immunohaematology products being diagnostic reagents; patient support servicesproviding patient medical information where patients can enquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community via an Internet-based database
Publicações
Histórico de despachos e eventos da marca no USPTO.
45 publicações encontradas
PRAN
POST REGISTRATION ACTION MAILED NO RESPONSE REQUIRED
29/06/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
20/11/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
17/11/2025
ES7R
TEAS SECTION 7 REQUEST RECEIVED
27/08/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/08/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
05/08/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
17/06/2025
PUBO
PUBLISHED FOR OPPOSITION
17/06/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/06/2025
ATRV
ATTORNEY REVIEW COMPLETED
29/05/2025
OTHE
CASE RETURNED TO EXAMINATION
27/05/2025
IUCN
NOTICE OF ALLOWANCE CANCELLED
27/05/2025
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
23/05/2025
PCBG
PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
23/05/2025
APET
ASSIGNED TO PETITION STAFF
19/05/2025
TPAD
TEAS PETITION TO AMEND BASIS RECEIVED
16/04/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
25/03/2025
EX2G
SOU EXTENSION 2 GRANTED
24/03/2025
EXT2
SOU EXTENSION 2 FILED
24/03/2025
EEXT
SOU TEAS EXTENSION RECEIVED
24/03/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
19/09/2024
EX1G
SOU EXTENSION 1 GRANTED
19/09/2024
EXT1
SOU EXTENSION 1 FILED
19/09/2024
EEXT
SOU TEAS EXTENSION RECEIVED
19/09/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
26/03/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
30/01/2024
PUBO
PUBLISHED FOR OPPOSITION
30/01/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/01/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/12/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
28/12/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
28/12/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
28/12/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
28/12/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/12/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/12/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/12/2023
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
15/08/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
15/08/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/06/2023
GNRT
NON-FINAL ACTION E-MAILED
05/06/2023
CNRT
NON-FINAL ACTION WRITTEN
05/06/2023
DOCK
ASSIGNED TO EXAMINER
30/05/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
30/08/2022
NWAP
NEW APPLICATION ENTERED
13/08/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CSL SEQIRUS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.